Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy PTC Therapeutics stock

Own PTC Therapeutics stock in just a few minutes.

PTC Therapeutics, Inc is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. PTC Therapeutics employs 959 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in PTC Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PTCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

PTC Therapeutics share price

Use our graph to track the performance of PTCT stocks over time.

PTC Therapeutics shares at a glance

Information last updated 2021-04-22.
52-week range$43.65 - $70.82
50-day moving average $51.81
200-day moving average $58.16
Wall St. target price$61.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.10

Buy PTC Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PTC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is PTC Therapeutics under- or over-valued?

Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PTC Therapeutics's PEG ratio

PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

PTC Therapeutics financials

Revenue TTM $380.8 million
Gross profit TTM $-62,219,000
Return on assets TTM -11.21%
Return on equity TTM -81.42%
Profit margin -115.07%
Book value $6.91
Market capitalisation $3.2 billion

TTM: trailing 12 months

Shorting PTC Therapeutics shares

There are currently 5.2 million PTC Therapeutics shares held short by investors – that's known as PTC Therapeutics's "short interest". This figure is 2.1% up from 5.1 million last month.

There are a few different ways that this level of interest in shorting PTC Therapeutics shares can be evaluated.

PTC Therapeutics's "short interest ratio" (SIR)

PTC Therapeutics's "short interest ratio" (SIR) is the quantity of PTC Therapeutics shares currently shorted divided by the average quantity of PTC Therapeutics shares traded daily (recently around 608783.89731622). PTC Therapeutics's SIR currently stands at 8.57. In other words for every 100,000 PTC Therapeutics shares traded daily on the market, roughly 8570 shares are currently held short.

However PTC Therapeutics's short interest can also be evaluated against the total number of PTC Therapeutics shares, or, against the total number of tradable PTC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PTC Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 PTC Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.076% of the tradable shares (for every 100,000 tradable PTC Therapeutics shares, roughly 76 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against PTC Therapeutics.

Find out more about how you can short PTC Therapeutics stock.

PTC Therapeutics share dividends

We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.

PTC Therapeutics share price volatility

Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $43.645 up to $70.82. A popular way to gauge a stock's volatility is its "beta".

PTCT.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 1.0662. This would suggest that PTC Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

PTC Therapeutics overview

PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site